Biomarkers are gaining recognition in the biotech and pharma community for their important role in advancing drug development. Increasingly, pharma is investing in the basic science discoveries that are necessary to identify suitable biomarkers for clinical use. This article points out four strategic considerations required in any successful biomarker program: choose the right application, validate the clinical predictability of the biomarker, engender biomarker adoption by industry and regulatory authorities quickly, and emphasize the financial value of the biomarker. Read ALS/MDA’s report on the current progress for ALS-specific biomarkers here (http://alsn.mda.org/article/als-biomarkers-aid-diagnosis-trials).
Click here to read more.Share this: